

February 17, 2015



# VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering

NAMUR, Belgium, Feb. 17, 2015 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that the underwriters of its [previously announced offering of common stock](#) have exercised the option to purchase an additional 343,383 shares at a price of \$3.75 per share.

National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (OTCBB: NHLD) and Lake Street Capital Markets acted as joint book running managers for the offering. The Benchmark Company acted as co-manager for the offering.

A registration statement on Form S-1 relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on February 5, 2015. Copies of the prospectus relating to the offering may be obtained by request to the offices of National Securities Corporation, Attn: Kim Addarich, Senior Vice President, 410 Park Avenue, 14th Floor, New York, NY 10022, Email: [Kaddarich@nhldcorp.com](mailto:Kaddarich@nhldcorp.com); or the offices of Lake Street Capital Markets, LLC, Attn: Equity Syndicate Department, 225 South 6th St, Ste 2050, Minneapolis, MN 55402, Telephone: (888) 330-4648, Email: [Contact@lakestreetcm.com](mailto:Contact@lakestreetcm.com); or the on the SEC's website at <http://www.sec.gov>.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted.

## About VolitionRx

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website ([www.volitionrx.com](http://www.volitionrx.com)) or connect with us via [Twitter](#), [LinkedIn](#) or [Facebook](#).

## Media Contacts

Charlotte Reynolds, VolitionRx

[Charlotte.Reynolds@volitionrx.com](mailto:Charlotte.Reynolds@volitionrx.com)

Telephone: +44 (0) 795 217 7498

Kirsten Thomas, The Ruth Group

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

Telephone: +1 (646) 536-7014

**Investor Contacts**

Scott Powell, Investor Relations

[S.Powell@volitionrx.com](mailto:S.Powell@volitionrx.com)

Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

Telephone: +1 (646) 536-7012

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/volitionrx-limited-announces-exercise-of-over-allotment-option-in-previously-announced-public-offering-300036858.html>

SOURCE VolitionRX Ltd